Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EBT (2018 - 2025)

BioNexus Gene Lab's EBT history spans 8 years, with the latest figure at -$1.0 million for Q4 2025.

  • Quarterly results put EBT at -$1.0 million for Q4 2025, down 145.51% from a year ago — trailing twelve months through Dec 2025 was -$3.0 million (down 87.14% YoY), and the annual figure for FY2025 was -$3.0 million, down 87.14%.
  • EBT for Q4 2025 was -$1.0 million at BioNexus Gene Lab, down from -$708991.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $370491.0 in Q3 2021 to a low of -$2.5 million in Q3 2023.
  • The 5-year median for EBT is -$105570.0 (2022), against an average of -$322388.7.
  • The sharpest move saw EBT surged 2696.19% in 2021, then plummeted 3664.13% in 2023.
  • Year by year, EBT stood at $197077.0 in 2021, then crashed by 164.67% to -$127451.0 in 2022, then skyrocketed by 298.96% to $253571.0 in 2023, then crashed by 266.44% to -$422032.0 in 2024, then plummeted by 145.51% to -$1.0 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$1.0 million, -$708991.0, and -$616172.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.